Yumeng Zhang, MD

Associations

• Malignant Hematology

Dr. Yumeng Zhang became an assistant member of the Malignant Hematology Department at the renowned H. Lee Moffitt Cancer Center and Research Institute in 2023. Prior to this, she had completed her hematology and medical oncology fellowship training at the same institution, where she excelled as a chief fellow. An unwavering passion for cancer immunology and the research of rare cancers drives Dr. Zhang's journey into oncology. Her innovative work in clinical trial design and translational oncology has earned her accolades such as the ASCO Young Investigator Award, the Robert A. Winn Diversity in Clinical Trials Award, and grants including the NIH K05 and the Microbiome Pilot Grant. She also participated in prestigious workshops like the ASCO/AACR Vail Workshop and the SCION Workshop.  Intrigued by the multifaceted nature of T-cell lymphoma, Dr. Zhang has outlined precise and ambitious objectives for her career. Her primary goal is to be recognized as a leading clinical investigator in the realm of T-cell lymphoma therapeutic development. Rather than solely relying on traditional treatment avenues, she emphasizes the integration of immune system modulation with targeted therapies. Such a pioneering approach sets the stage for groundbreaking therapeutic advancements in T-cell lymphoma. Furthermore, Dr. Zhang is dedicated to refining the treatment and management strategies for rare cancers, such as cutaneous T-cell lymphoma. She aspires to develop or augment a research platform designed explicitly for these rare malignancies. This envisioned platform promises to be pivotal in addressing the current challenges associated with these uncommon diseases' management and therapeutic evolution. Endowed with a drive for cancer immunology and rare cancer research and equipped with the extensive clinical experience gained at the H. Lee Moffitt Cancer Center and Research Institute, Yumeng Zhang is well on the way to making significant contributions to the field of oncology.

• Rutenberg D, Zhang Y, Montoya JG, Sinnott J, Contopoulos-Ioannidis DG. The Meat of the Matter. N Engl J Med. 2024 May.390(17):1612-1618. Pubmedid: 38692295.
• Zhang Y, Rose A, Khadka S, Cao B, Eatrides J, Saeed H, Shah BD, Chavez J, Bello C, Lazaryan A, Khimani F, Ibarz JP, Liu HD, Locke FL, Jain MD, Zhang L, Kharfan-Dabaja MA, Kim J, Ayala E, Nishihori T, Sokol L. Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell Lymphoma. Transplant Cell Ther. 2024 May. Pubmedid: 38740140.
• Zhang Y, Darville L, Hogue S, Hallanger Johnson JE, Rose T, Kim Y, Bailey A, Gray JE, Robinson LA. High Pretreatment DHEA Is Associated with Inferior Immunotherapy Response in Metastatic Non-Small Cell Lung Cancer. Cancers (Basel). 2024 Mar.16(6). Pubmedid: 38539486. Pmcid: PMC10968948.
• Harro CM, Sprenger KB, Chaurio RA, Powers JJ, Innamarato P, Anadon CM, Zhang Y, Biswas S, Mandal G, Mine JA, Cortina C, Nagy MZ, Martin AL, Handley KF, Borjas GJ, Chen PL, Pinilla-Ibarz J, Sokol L, Yu X, Conejo-Garcia JR. Sézary syndrome originates from heavily mutated hematopoietic progenitors. Blood Adv. 2023 Sep.7(18):5586-5602. Pubmedid: 37531660. Pmcid: PMC10514084.
• Zhang Y, Nguyen L, Lu CM, Wang E, Lauw MIS, Ball S, Dong N, Moscinski L, Chan O, Yun S, Sallman D, Sokol L, Shah B, Knepper T, Lancet J, Komrokji R, Padron E, Kuykendall A, Zhang L. Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion. Clin Lymphoma Myeloma Leuk. 2023 Mar.23(3):e150-e163. Pubmedid: 36624015.
• Zhang L, Shah B, Zhang Y, Tashkandi H, Xiao W, Fernandez-Pol S, Vergara-Lluri M, Hussaini M, Song J, Lancet J, Moscinski L, Yun S, Lu CM, Medeiros LJ, Tang G. Clinicopathologic characteristics, genetic features, and treatment options for acute lymphoblastic leukemia with JAK2 rearrangement-A 10-case study and literature review. Hum Pathol. 2023 Jun.136:1-15. Pubmedid: 36958463.
• Ball S, Jain AG, Aguirre LE, Al Ali N, Zhang Y, Chan O, Kuykendall AT, Sweet KL, Lancet JE, Swoboda DM, Padron E, Komrokji RS, Sallman DA. Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?. Am J Hematol. 2022 May.97(5):E185-E188. Pubmedid: 35179241.
• Zhang Y, Seminario-Vidal L, Cohen L, Hussaini M, Yao J, Rutenberg D, Kim Y, Giuliano A, Robinson LA, Sokol L. "Alterations in the Skin Microbiota Are Associated With Symptom Severity in Mycosis Fungoides". Front Cell Infect Microbiol. 2022 May.12:850509. Pubmedid: 35656034. Pmcid: PMC9152451.
• Zhang Y, Sokol L. Clinical Insights into the Management of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancer Manag Res. 2022 Jun.14:2107-2117. Pubmedid: 35789956. Pmcid: PMC9250318.
• Zhang Y, Seminario-Vidal L, Varnadoe C, Lu Y, Dong N, Salamanca C, Whiddon S, Bennett J, Hargis R, Liu H, Montejo M, Hussaini M, Harro C, Messina J, Benson K, Pinilla-Ibarz J, Conejo-Garcia J, Sokol L. Clinical characteristics and prognostic factors of 70 patients with Sézary syndrome: a single-institutional experience at Moffitt cancer center. Leuk Lymphoma. 2022 Jan.63(1):109-116. Pubmedid: 34467825. Pmcid: PMC9167451.
• Zhang Y, Duncanson L, Brayer J, Reu F, Hansen D, Alsina M, Nishihori T, Ochoa-Bayona J, Liu H, Shain K, Thompson Z, Baz R, Blue B. Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study. Clin Lymphoma Myeloma Leuk. 2022 Aug.22(8):e770-e776. Pubmedid: 35504808.
• Zhang Y, Kumar P, Adashek JJ, Skelton WP, Li J, Vosoughi A, Chahoud J, Manley BJ, Spiess PE. Adding Cyclooxygenase Inhibitors to Immune Checkpoint Inhibitors Did Not Improve Outcomes in Metastatic Renal Cell Carcinoma. Cells. 2022 Aug.11(16). Pubmedid: 36010582. Pmcid: PMC9406439.
• Gesiotto Q, Zhang Y, Malik A, Seminario-Vidal L, Ayala E, Zhang L, Sokol L. Long-Term Remission After Matched Sibling Donor Hematopoietic Cell Transplantation in a Patient With Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma. Cureus. 2021 May.13(5):e15132. Pubmedid: 34159034. Pmcid: PMC8214246.
• Dong N, Castillo Tokumori F, Isenalumhe L, Zhang Y, Tandon A, Knepper TC, Mo Q, Shao H, Zhang L, Sokol L. Large granular lymphocytic leukemia - A retrospective study of 319 cases. Am J Hematol. 2021 Jul.96(7):772-780. Pubmedid: 33819354.
• Adashek JJ, Zhang Y, Skelton WP, Bilotta A, Chahoud J, Zemp L, Li J, Dhillon J, Manley B, Spiess PE. Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation?. Front Oncol. 2021 Feb.10:627025. Pubmedid: 33643921. Pmcid: PMC7902859.
• Zhang Y, Lee D, Gesiotto Q, Sokol L. Aggressive natural killer cell leukemia: diagnosis, treatment recommendations, and emerging therapies. Expert Rev Hematol. 2021 Aug.14(8):731-740. Pubmedid: 34263714.
• Visweshwar N, Zhang Y, Joseph H, Jaglal M, Ayala I. Chronic pain in patients with hemophilia: is it preventable?. Blood Coagul Fibrinolysis. 2020 Sep.31(6):346-352. Pubmedid: 32815911.
• Zhang Y, Varnadoe C, Tandon A, Forsyth P, Komrokji R, Sokol L. Myasthenia Gravis and Large Granular Lymphocytic Leukemia: a rare association. Leuk Res Rep. 2020 Oct.14:100226. Pubmedid: 33094093. Pmcid: PMC7568180.
• Zhang Y, Lee D, Brimer T, Hussaini M, Sokol L. Genomics of Peripheral T-Cell Lymphoma and Its Implications for Personalized Medicine. Front Oncol. 2020 Jun.10:898. Pubmedid: 32637355. Pmcid: PMC7317006.
• Zhang Y, Song J, Rutenberg D, Sokol L. Hepatic Infiltration with Malignant T-cells Manifesting as Impending Acute Liver Failure in Sezary Syndrome. Mediterr J Hematol Infect Dis. 2020 Jan.12(1):e2020007. Pubmedid: 31934317. Pmcid: PMC6951350.
• Visweshwar N, Zhang Y, Joseph H, Jaglal M, Ayala I. Chronic pain in patients with hemophilia: is it preventable?. Blood Coagul Fibrinolysis. 2020 Aug.31(6):346-352. Pubmedid: 32804455.
• Zhang Y, Swoboda DM, Grover A, Nodzon L, Zhang L, Pinilla-Ibarz J. T315I-mutated myeloid sarcoma. Leuk Res Rep. 2019 Aug.12:100184. Pubmedid: 31485411. Pmcid: PMC6715886.

• Title: Enhancing Patient Diversity in the PLIGHT Trial: A Multilevel Strategy for Inclusive Enrollment for Asian Population in the Concurrent Phototherapy and POTELIGEO (mogamulizumab-kpkc) Pilot Study for Early-Stage Mycosis Fungoides
  Sponsor: Bristol Myers Squibb Foundation
  PI: Zhang, Y.
• Title: Evaluating Molecular Biology of Clonal Large Granular Lymphocytic (LGL) Proliferations in Peripheral Blood in Patients with Mycosis Fungoides/Sezary Syndrome (MF/SS)
  Sponsor: Amer Society of Clinical Oncology (ASCO)
  PI: Zhang, Y.